王前奔，男，博士生导师，中国医学科学院基础医学研究所/北京协和医学院基础学院长聘教授。2002年获美国马里兰大学巴尔的摩分校博士学位，2003–2008年在哈佛大学Dana-Farber肿瘤研究所从事博士后研究，并任哈佛大学医学院讲师。此后历任美国俄亥俄州立大学医学院分子和细胞生物化学系助理教授（预备终身教职）、分子和细胞生物化学系及肿瘤生物学与遗传学系副教授（终身教职），以及杜克大学医学院病理学系终身正教授和冠名讲席教授。2025年8月全职回国，加入中国医学科学院基础医学研究所/北京协和医学院基础学院。

      王前奔教授长期从事肿瘤基因调控与可编程RNA治疗研究，以前列腺癌等激素相关肿瘤为主要研究基础，重点解析肿瘤发生发展、转移、治疗耐药和免疫逃逸过程中的转录、表观遗传及转录后调控机制。团队目前正将相关研究拓展至小细胞肺癌等高度恶性肿瘤，重点研究其关键基因调控机制及其在肿瘤进展和治疗抵抗中的作用。

     近年来，团队将CRISPR–Cas13 RNA工程与脂质纳米颗粒递送技术相结合，构建了可编程RNA精准治疗平台，用于靶向疾病驱动RNA及传统上难以成药的转录因子等关键靶点，推动肿瘤机制研究向精准干预和创新治疗转化。相关研究成果发表于《Cell》《Nature Biomedical Engineering》《Nature Genetics》《Nature Chemical Biology》《Molecular Cell》《Cell Research》《PNAS》《Nature Communications》《EMBO Journal》《Cancer Research》《Advanced Science》和《Nano Research》等国际期刊。

   王前奔教授曾任美国基础泌尿科学研究学会（SBUR）常务董事、执行委员会委员，并担任2025年第33届SBUR年会主席。曾任美国国立卫生研究院（NIH）肿瘤基因调控学科评审组常任委员及杜克大学医学院临床科学终身教授评审委员会委员。曾主持多项美国NIH U54、R01和DoD研究项目。获2025年美国基础泌尿科学研究学会（SBUR）杰出研究成就奖（Meritorious Achievement Award），入选2025年度国家级领军人才项目，并于2026年当选美国医学与生物工程院会士（AIMBE Fellow）。

PUBLICATIONS

1. Huang F, Yuan F, Li K, Cui Y, Li L, Ye W, Cui Z, Yan J, Chen Q, Nicchitta C, Zhang Y, Hankey W, Everitt J, Huang KL, Wang ME, Chen M, Huang J, Wang H, Wagner EJ, Lu X, Dong Y*, Li W* and Wang Q*. Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer. Nature Biomedical Engineering, 2026 Jun 16. doi: 10.1038/s41551-026-01720-9. (*Corresponding authors)

2. Cui Z, Huang F, Fang K, Yan J, Zhang Y, Kang DD, Zhou Y, Zhao Y, Everitt JI, Hankey W, Armstrong AJ, Huang J, Wang H, Jin VX, Dong Y* and Wang Q*. SCORT-Cas13d nanotherapy precisely targets the 'undruggable' transcription factor HoxB13 in metastatic prostate cancer in vivo. Advanced Science, 2025 Jun;12(23):e2417605. doi: 10.1002/advs.202417605. (*Corresponding authors)

3. Huang F, Li K, Shevach JW and Wang Q. Emerging Therapies to Overcome Antiandrogen Resistance and Beyond in Lethal Prostate Cancer (invited review article). Journal of the National Cancer Center, 2025 May 24;6(1):42-57. doi: 10.1016/j.jncc.2025.04.004.

4. Cui Z, Liu T, Bacon R, Zhao Y, Everitt JI, Yan J, Chen L, Wang H, Dong Y*, Jin VX*, Liu SL*, and Wang Q*. Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters. Nano Research, 2025 Sep;18(9):94907695. doi: 10.26599/NR.2025.94907695. (*Corresponding authors)

5. Zhou BR, Feng H, Huang F, Zhu I, Shi D, Zaret KS, Landsman D, Wang Q, and Bai Y. Structural insights for the cooperative nucleosome recognition and chromatin opening by FoxA1 and GATA4. Molecular Cell, 2024 Aug 22;84(16):3061-3079.e10. doi: 10.1016/j.molcel.2024.07.016.

6. Cui Z, Zeng C, Huang F, Yuan F, Yan J, Zhao Y, Zhou Y, Hankey W, Jin VX, Huang J, Staats HF, Everitt JI, Sempowski GD, Wang H, Dong Y*, Liu SL* and Wang Q*. Cas13d knockdown of lung protease Ctsl prevents and treats lethal SARS-CoV-2 infection. Nature Chemical Biology, 2022 Oct;18(10):1056-1064. doi: 10.1038/s41589-022-01094-4. (*Corresponding authors)

7. Li T, Liu Q, Chen Z, Fang K, Huang F, Fu X, Wang Q*, and Jin VX*. Dynamic nucleosome landscape elicits a novel noncanonical GATA2 pioneer model. Nature Communications, 2022 Jun 7;13(1):3145. doi: 10.1038/s41467-022-30960-x. (*Corresponding authors)

8. Chen Z*, Hankey W, Zhao Y, Groth J, Wang H, Huang J, Roeder RG, and Wang Q*. Transcriptional recycling assays identify PAF1 as a driver of RNA Pol II recycling. Nature Communications, 2021 Nov 3;12(1):6318. doi: 10.1038/s41467-021-26604-1. (*Corresponding authors)

9. Huang F, Chen H, Zhu X, Gong T, Li X, Hankey W, Ding D, Wang H, Chen Z*, Wang Q*, and Liu Z*. The oncogenic function of androgen receptor in esophageal squamous cell carcinoma is directed by GATA3. Cell Research, 31:362-365, 2021. doi: 10.1038/s41422-020-00428-y. (*Corresponding authors)

10. Yuan F, Hankey W, Wu D, Wang H, Somarelli J, Armstrong AJ, Huang J, Chen Z, Wang Q. Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Research, 47: 10104-10114, 2019

11. Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, Cheng X, Antonarakis ES, Wang QE, Liu Z, Huang THM, Jin VX, Clinton SK, Luo J*, Huang J*, Wang Q*. Diverse AR-V7 cistromes in castration-resistant prostate cancer growth are governed by HoxB13. Proc Natl Acad Sci USA, 115: 6810-6815, 2018. (*Corresponding authors)

12. Chen Z*, Lan X, Wu D, Sunkel B, Ye Z, Huang J, Liu Z, Clinton SK, Jin VX and Wang Q*. Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. Nature Communications, 6: 8323, 2015 (*Corresponding authors)

13. Chen K, Chen Z, Wu D, Zhang L, Lin X, Su J, Rodriguez B, Xi Y, Xia Z, Chen X, Shi X, Wang Q* and Li W*. Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. Nature Genetics, 47: 1149-1157, 2015 (*Corresponding authors)

14. Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, Wang L, Sunkel B, Grenade C, Chen J, Zynger DL, Yan PS, Huang, J, Nephew KP, Huang THM, Lin S, Clinton SK, Li W, Jin VX and Wang Q. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer, EMBO Journal, 34: 502-516, 2015.

15. Wu D, Sunkel B, Chen Z, Li Q, Cassandra G, Ye Z, Ke J, Chen H, Nephew KP, Huang THM, Liu Z, Jin VX and Wang Q. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Research, 42: 3607-3622, 2014. (NAR Breakthrough Article)

16. Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, and Wang Q. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO Journal, 30:2405-2419, 2011.

17. Wang Q*^, Li, W^, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Wu T, Lupien M, Carroll JS, Manrai AK, Janne OA, Balk SP, Mehra R, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS*, and Brown M*. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138:245-256, 2009. (*Corresponding authors, ^ First authors) (Cell Featured Article)

PATENTS

1. Wang Q., Li W., Yuan F. 3′UTR CRISPR-dCas13 Engineering System and Methods of Using Same. US Patent, No.12,467,043 B2, 2025.

2. Wang Q., Cui Z., Dong Y. Nanoparticle Systems for Targeted Delivery of CRISPR/Cas13 and Methods of Using Same. US Patent, No. 12,521,355 B2, 2026.

团队目前有1名副研究员、1名科研人员、1名主管技师、1名科研助理、2名博士研究生。